Search results with tag "Votrient"
NEW ZEALAND DATA SHEET VOTRIENT 200 mg and 400 mg …
www.medsafe.govt.nzNEW ZEALAND DATA SHEET VOTRIENT® Film coated tablet Page 4 of 27 VOTRIENT is contraindicated in patients with hypersensitivity to the active substance pazopanib hydrochloride or to any of the excipients listed in section 6.1.
Enrollment Application for the Novartis Patient Assistance ...
www.novartis.usVOTRIENT® (pazopanib) tablets ZOMETA® (zoledronic acid) for injection ZORTRESS® (everolimus) ZYKADIA® (ceritinib) capsules *Additional products may be available. Please check the NPAF website at www.pap.novartis.com for the …
Q4 2020 Results - Novartis
www.novartis.com- Renewed listing: Tasigna ®, Votrient , Sandostatin® LAR, Zykadia® Rich pipeline: - 2020 NDA approvals: Cosentyx ®AS, Mayzent , Pataday®, Tafinlar®+Mekinist® adj, Zykadia ® 1L - 7 approvals expected in 2021 (NDA submitted in 2020) - Kesimpta® granted China priority review, TQJ230 obtained 1st BTD
Drugs that Can Affect Blood Glucose Levels
www.diabetesincontrol.comPazopanib (Votrient ®) Pentamidine (Nebupent®, Pentam 300®) Phenytoin (Dilantin®, Dilantin-125®, Dilantin Infatabs®, Dilantin Kapseals®, Phenytek®) Ponatinib Rifampin (Rifadin®, Rimactane®) Ritodrine (Yutopar®) Rituximab (Rituxan®) Salsalate (Argesic®-SA, Disalcid®, Mono-Gesic®, Salflex®,Salsitab®)
DRUG NAME: Pazopanib
www.bccancer.bc.caVOTRIENT® CLASSIFICATION: vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Pazopanib is an orally active tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR-1,-2, -